Study to Evaluate EnteroTracker® as a Sampling Method to Screen for Barrett's Esophagus/Esophageal Cancer
At a glance
Conditions
NCT05706025
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Colorado
Aurora, Coloradono site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Sachin Wani, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Study Esophageal Mucosal Samples using Enterotracker Device2 years
Capture esophageal mucosal samples in at least 50% of the test subjects using the EnteroTracker®.
- Testing Tolerability via "Post-Procedure Tolerability Survey"2 years
At least 50% of subjects describe the EnteroTracker® as "Satisfactory" from taking a "Post-Procedure Tolerability Survey".
- Testing difference in Biomarkers between Control and BE/EAC patients2 years
At least one biomarker differentiated between BE/EAC patients and control subjects in at least 50% of test subjects. Samples will be analyzed for various biomarkers including proteins, DNA, RNA and/or methylation of DNA.